Harrow closes TYRVAYA nasal spray acquisition from Viatris for USD 30 million upfront

By Public Technologies
  • Harrow closed its acquisition of TYRVAYA (varenicline solution) nasal spray 0.03 mg from Viatris, gaining worldwide rights except Japan.
  • Viatris retained Japan commercialization rights, agreeing to pay Harrow royalties on any future net sales there.
  • Deal terms include USD 30 million cash paid at closing, with up to USD 70 million tied to net-sales milestones.
  • Harrow expects TYRVAYA revenue to exceed USD 30 million in 2027 as it integrates the brand into its ocular surface franchise.
  • Roughly 40 Viatris personnel are expected to join in Q4 2026 to expand Harrow’s dry-eye commercial team.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050700PRIMZONEFULLFEED9839258) on October 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.